###### Strengths and limitations of this study

-   We studied 48-month risk of virological failure (VF) and HIV drug resistance (HIVDR) and their associations with demographic and behavioural information among individuals across five sentinel sites.

-   Study found drug adherence and adverse effects influenced VF and HIVDR differently across gender.

-   The outcomes were measured in 2011 and 2012, and thus we may be missing transient VF outcomes.

Introduction {#s1}
============

Antiretroviral treatment (ART) has dramatically improved health outcomes and decreased HIV-associated morbidity and mortality through virological suppression and subsequent CD4 recovery.[@R1] In 2003, China launched a National Free Antiretroviral Treatment Program (NFATP) that includes lifelong provision of free ART for people living with HIV who met the national treatment criteria.[@R5] The national treatment criteria from 2008 to 2011 were: (1) CD4 cell count ≤0.2x10\^9/L; (2) WHO stage III/IV diseases; or (3) willingness to receive ART, regardless of criteria 1 and 2.[@R7]

The State Council AIDS Working Committee Office and the United Nations Theme Group on AIDS estimated that there were more than 700 000 persons living with HIV in China in 2008, and more than 52 000 individuals with HIV across 31 provinces, autonomous regions and municipalities had received ART (made freely available by the NFATP) by August 2008.[@R8]

With the rapid scale-up of treatment and challenges with adherence, virological failure (VF) and HIV drug resistance (HIVDR) are ever present and mounting concerns. Incomplete virological suppression, a major cause of HIVDR, compromises therapeutic efficacy for the individual receiving treatment, increasing the risk of viral rebound and opportunistic infections, and increases the risk of transmitting drug-resistant strains to other individuals in the general population.[@R9]

Observational studies in China have documented the prevalence of VF and HIVDR strains among treated individuals living with HIV. A cross-sectional study conducted in Yunnan, Guangxi and Xinjiang provinces in 2010 stated that 1-year HIVDR prevalence was 4.1%.[@R5] VF prevalence for sexual transmitted population and intravenous drug users (IDUs) was 8.3% and 19.3%, separately. A 6-year follow-up study in 2010 suggested an incidence of 14.1 per 100 person-years for VF and 11.9 per 100 person-years for HIVDR among former plasma donors in Anhui Province.[@R12]

NFATP recommended to switch the first-line regimen from didanosine to lamivudine (3TC) in 2008, and there are few nationwide, prospective studies in China reporting frequency or predictors of VF and HIVDR for people after initiating 3TC-based regimens.

The aim of this study is to evaluate predictors of VF and HIVDR in a prospective cohort of Chinese HIV individuals with HIV 4 years after first initiating first-line 3TC-based ART in 2008 at five sentinel sites. We stratified our analyses by gender based on conflicting findings on gender differences both in virological responses and drug resistance to different ART regimen, as well as gender differences in ART adherence.[@R13] To our knowledge, this is the first long-term study to evaluate VF and HIVDR on 3TC-based regimens.

Ethics statement {#s2}
================

The study was approved by the Institutional Review Board of the National Center for AIDS/STD Control and Prevention of the Chinese Center for Disease Control and Prevention (NCAIDS, China CDC). All participants provided written informed consent before participation. Signed informed consent was obtained from each of the participants prior to the interviews and blood collection.

Methods {#s3}
=======

Study design and data collection {#s3a}
--------------------------------

This study was designed under the WHO surveillance of HIVDR in adults receiving ART for 48 months.[@R10] Five provinces in China with highest rate of transmission were selected to conduct a prospective cohort study with a follow-up study at 12 months: Guangxi, Henan, Hubei, Xinjiang and Yunnan. Participants were sampled from the 2008 National HIV Surveillance Database through sequential sampling from each province. Participant eligibility criteria included being aged ≥18 years; having initiated NFATP-sponsored first-line ART in 2008; having been ART free before 2008; having been on ART for 36±6 months in 2011; and providing consent to participate in the study.

Questionnaires administered by trained study personnel from provincial CDC in private rooms using structured interviews collected data in 2011 and 2012. Each study participant was assigned a confidential identification number used to label questionnaire and blood specimen. Additional HIV-specific data including route of transmission, initial ART regimen, latest ART regimen, ART distribution location and CD4 cell count were collected from the 2011--2012 National HIV Surveillance Database. There were no missing demographic data, missed questionnaire data were fed back to local CDC for recollection at the time.

Laboratory analysis {#s3b}
-------------------

Blood specimens were collected from all participants to determine CD4 cell count, HIV-1 RNA viral load (VL) and HIV-1 drug resistance mutations in both 2011 and 2012. CD4 cell count estimation was conducted at provincial CDC laboratories using flow cytometry (FACSCalibur, BD, USA) within 24 hours after specimen collection. Plasma was isolated and stored at −80°C at a provincial CDC laboratory and then transferred to NCAIDS for testing HIV VL and drug mutation. Plasma HIV RNA was quantified with real-time NASBA (NucliSENS EasyQ, bioMerieux, France) or COBAS (Roche Applied Biosystems, Germany) according to manufacturer's recommendations using in-house PCR, both of the assays were performed automatically.[@R19] VF was defined as VL ≥1000 copies/mL. According to WHO protocol,[@R20] HIVDR tests were performed on samples with VL ≥1000 copies/mL. HIV-1 *pol* gene (protease 1--99 amino acids and part of reverse-transcriptase 1--252 amino acids) was amplified, purified and analysed using the Stanford HIV Drug Resistance Database (<https://hivdb.stanford.edu/hivdb>). Levels of HIVDR were classified according to the algorithm of Stanford HIVdb program. The scores are the sum of each mutation penalty score for a drug. Scores less than 10 indicate susceptible; scores between 10 and 14 indicate potential low-level resistance; scores between 15 and 29 indicate low-level resistance; scores between 30 and 59 indicate intermediate resistance. Scores of 60 or greater indicate high-level resistance. Any low, intermediate or high-level resistance identified was defined as HIVDR.[@R21]

Data analysis {#s3c}
-------------

Questionnaire data were double entered using EpiData V.3.1 (The EpiData Association, Odense, Denmark). Statistical Analysis System (SAS V.9.4, SAS Institute) was then used for data cleaning and analyses.

A 48-month risk for the outcomes of interest was calculated as the proportion of unique persons who had experienced incident VF or HIVDR by the end of follow-up in 2012.

Covariates of interest were described using counts and percentages overall and by the outcome of interest, stratified by gender. Univariate logistic regression models were constructed to explore associations between covariates of interest and VF or HIVDR. OR and 95% CIs are reported. Variables that were significant (p\<0.05) in the univariate models were then fit into multivariate logistic regression models assessment for removal of collinear variables that had the weakest association with the outcome. Adjusted ORs (aOR) and 95% CIs were presented. p\<0.05 was defined as statistically significant, and all tests were two sided. Descriptive analysis on HIVDR mutation results was conducted among 27 HIVDR participants, stratified by sex.

Results {#s4}
=======

Up to 1100 subjects were selected using consecutive ID numbers from 2008 National Surveillance Database; of those, 490 were lost to follow-up by December 2012. Among those lost to follow-up, 139 died, 55 emigrated, 134 lost contact, 17 refused to participate, 65 stopped ART before 30 months, 36 transferred, 8 were under custody, 6 failed to provide a blood sample, 3 switched from ART to Tangcao tablet (an antiviral Chinese herbal therapy), 2 became pregnant and switched to other regimens and 1 was paralysed. After excluding 74 participants for failing the eligibility criteria, 536 participants were included in the final 24-month analysis ([figure 1](#F1){ref-type="fig"}). The 48-month risk of VF was 11.8% and risk of drug resistance was 5%.

![Figure of exclusion on study cohort. ^1^None HIV-related death. ART, antiretroviral treatment; DDI, didanosine. ](bmjopen-2017-016012f01){#F1}

Demographic and ART information ([tables 1 and 2](#T1 T2){ref-type="table"}) {#s4a}
----------------------------------------------------------------------------

###### 

Factors associated with virological failure (viral load ≥1000 copies/mL) stratified by sex

                                                               Female   Male                                                                           
  ------------------------------------------------------------ -------- ----------- ------------------- -------- ----- ----------- ------------------- --------
  Total                                                        258      29 (11.2)                                278   34 (12.2)                       
  *Demographic factors*                                                                                                                                
  Ethnicity                                                                                                                                            
   Han nationality                                             191      19 (9.9)    1                            219   20 (9.1)    1                   
   Other minorities                                            67       10 (14.9)   1.6 (0.7 to 3.6)    0.27     59    14 (23.7)   3.1 (1.5 to 6.6)    \<0.01
  Education                                                                                                                                            
   Elementary school or less                                   134      15 (11.2)   1                            107   12 (11.2)   1                   
   Junior school or more                                       124      14 (11.3)   1 (0.5 to 2.2)      0.98     171   22 (12.9)   1.2 (0.6 to 2.5)    0.68
  Marital status                                                                                                                                       
   Single                                                      59       6 (10.2)    1                            75    9 (12)      1                   
   Married or cohabited                                        199      23 (11.6)   1.2 (0.4 to 3.0)    0.77     203   25 (12.3)   1 (0.5 to 2.3)      0.94
  Residence                                                                                                                                            
   Rural                                                       197      19 (9.6)    1                            172   17 (9.9)    1                   
   City                                                        61       10 (16.4)   1.8 (0.8 to 4.2)    0.15     106   17 (16)     1.7 (0.8 to 3.6)    0.13
  Occupation                                                                                                                                           
   Peasant                                                     163      15 (9.2)    1                            138   9 (6.5)     1                   
   Employee                                                    64       11 (17.2)   2 (0.9 to 4.7)      0.09     114   17 (14.9)   2.5 (1.1 to 5.9)    0.03
   Unemployed                                                  31       3 (9.7)     1.1 (0.3 to 3.9)    0.93     26    8 (30.8)    6.4 (2.2 to 18.6)   \<0.01
  Age (years)                                                                                                                                          
   \<35                                                        73       6 (8.2)     1                            53    7 (13.2)    1                   
   35--45                                                      108      15 (13.9)   1.8 (0.7 to 4.9)    0.25     119   15 (12.6)   0.9 (0.4 to 2.5)    0.91
   \>45                                                        77       8 (10.4)    1.3 (0.4 to 3.9)    0.65     106   12 (11.3)   0.8 (0.3 to 2.3)    0.73
  Weight (kg)                                                                                                                                          
   \<50                                                        89       14 (15.7)   1                            49    7 (14.3)    1                   
   50--70                                                      156      13 (8.3)    0.5 (0.2 to 1.1)    0.08     193   21 (10.9)   0.7 (0.3 to 1.8)    0.51
   \>70                                                        13       2 (15.4)    1 (0.2 to 4.9)      0.97     36    6 (16.7)    1.2 (0.4 to 3.9)    0.76
  *HIV characteristics and treatment factors*                                                                                                          
  Route of infection                                                                                                                                   
   Heterosexual transmission                                   159      12 (7.5)    1                            154   11 (7.1)    1                   
   Blood transmission                                          86       13 (15.1)   2.2 (0.9 to 5)      0.07     61    10 (16.4)   2.5 (1 to 6.4)      0.04
   Intravenous drug use                                        13       4 (30.8)    5.4 (1.5 to 20.3)   0.01     63    13 (20.6)   3.4 (1.4 to 8)      0.01
  Initial NRTI ART regimen                                                                                                                             
   AZT-based regimen                                           161      11 (6.8)    1                            188   26 (13.8)   1                   
   D4T-based regimen                                           97       18 (18.6)   3.1 (1.4 to 6.9)    \<0.01   90    8 (8.9)     0.6 (0.3 to 1.4)    0.24
  Latest NRTI ART regimen                                                                                                                              
   AZT-based regimen                                           181      15 (8.3)    1                            195   27 (13.8)   1                   
   D4T-based regimen                                           77       14 (18.2)   2.5 (1.1 to 5.4)    0.02     83    7 (8.4)     0.6 (0.2 to 1.4)    0.21
  Switch ART regimen                                                                                                                                   
   No                                                          193      21 (10.9)   1                            174   21 (12.1)   1                   
   Yes                                                         65       8 (12.3)    1.2 (0.5 to 2.7)    0.75     104   13 (12.5)   1 (0.5 to 2.2)      0.92
  ART drug distribution location                                                                                                                       
   County hospital or CDC                                      96       15 (15.6)   1                            63    14 (22.2)   1                   
   Township hospital/village clinic/medication monitor         162      14 (8.6)    0.5 (0.2 to 1.1)    0.09     215   20 (9.3)    0.4 (0.2 to 0.8)    0.01
  Adverse effects                                                                                                                                      
   No                                                          195      17 (8.7)    1                            206   23 (11.2)   1                   
   Yes                                                         63       12 (19)     2.5 (1.1 to 5.5)    0.03     72    11 (15.3)   1.4 (0.7 to 3.1)    0.36
  CD4 cell/mL at baseline (2008)                                                                                                                       
   \<350                                                       244      28 (11.5)   1                            272   31 (11.4)   1                   
   ≥350                                                        14       1 (7.1)     0.6 (0.1 to 4.7)    0.62     6     3 (50)      7.8 (1.5 to 40.2)   0.01
  CD4 cell/mL at 36 months (2011)                                                                                                                      
   0--350                                                      91       18 (19.8)   1                            138   21 (15.2)   1                   
   ≥350                                                        167      11 (6.6)    0.3 (0.1 to 0.6)    \<0.01   140   13 (9.3)    0.6 (0.3 to 1.2)    0.13
  CD4 cell/mL at 48 months (2012)                                                                                                                      
   0--350                                                      81       14 (17.3)   1                            122   20 (16.4)   1                   
   ≥350                                                        177      15 (8.5)    0.4 (0.2 to 1)      0.04     156   14 (9)      0.5 (0.2 to 1)      0.06
  *Drug compliance factors*                                                                                                                            
  Missed doses in past month                                                                                                                           
   No                                                          226      26 (11.5)   1                            246   24 (9.8)    1                   
   Yes                                                         32       3 (9.4)     0.8 (0.2 to 2.8)    0.72     32    10 (31.3)   4.2 (1.8 to 9.9)    \<0.01
  Willing to receive ART in the future                                                                                                                 
   Always                                                      153      15 (9.8)    1                            177   19 (10.7)   1                   
   Not always                                                  105      14 (13.3)   1.4 (0.7 to 3.1)    0.38     101   15 (14.9)   1.5 (0.7 to 3)      0.32
  Believe ART is health promoting                                                                                                                      
   Always                                                      158      16 (10.1)   1                            181   19 (10.5)   1                   
   Not always                                                  100      13 (13)     1.3 (0.6 to 2.9)    0.48     97    15 (15.5)   1.6 (0.8 to 3.2)    0.24
  Believe poor compliance contributes to HIVDR                                                                                                         
   Always                                                      139      16 (11.5)   1                            169   19 (11.2)   1                   
   Not always                                                  119      13 (10.9)   0.9 (0.4 to 2.1)    0.88     109   15 (13.8)   1.3 (0.6 to 2.6)    0.53
  Degree of satisfaction on support of friends or relatives                                                                                            
   Always satisfied                                            153      15 (9.8)    1                            166   17 (10.2)   1                   
   Not always satisfied                                        105      14 (13.3)   1.4 (0.7 to 3.1)    0.38     112   17 (15.2)   1.6 (0.8 to 3.2)    0.22
  Frequency of taking drugs reminded by friends or relatives                                                                                           
   Often                                                       172      19 (11)     1                            168   22 (13.1)   1                   
   Not often                                                   86       10 (11.6)   1.4 (0.7 to 3.1)    0.38     110   12 (10.9)   0.8 (0.4 to 1.7)    0.58
  Frequency of taking drugs reminded by doctors                                                                                                        
   Often                                                       178      23 (12.9)   1                            184   28 (15.2)   1                   
   Not often                                                   80       6 (7.5)     0.5 (0.2 to 1.4)    0.19     94    6 (6.4)     0.4 (0.2 to 1)      0.03

ART, antiretroviral treatment; AZT, zidovudine; CDC, Centers for Disease Control and Prevention; D4T, stavudine; HIVDR, HIV drug resistance; NRTI, nucleoside reverse-transcriptase inhibitors.

###### 

Factors associated with HIVDR (viral load ≥1000 copies/mL with drug resistance) stratified by sex

                                                Female   Male                                                                        
  --------------------------------------------- -------- ---------- ------------------- ------ ----- ---------- -------------------- --------
                                                258      14 (5.4)                              278   13 (4.7)                        
  *Demographic factors*                                                                                                              
  Ethnicity                                                                                                                          
   Han nationality                              191      6 (3.1)    1                          219   5 (2.3)    1                    
   Other minorities                             67       8 (11.9)   4.2 (1.4 to 12.5)   0.01   59    8 (13.6)   6.7 (2.1 to 21.4)    \<0.01
  Education                                                                                                                          
   Elementary school or less                    134      5 (3.7)    1                          107   5 (4.7)    1                    
   Junior school or more                        124      9 (7.3)    2 (0.7 to 6.2)      0.22   171   8 (4.7)    1 (0.3 to 3.1)       1
  Marital status                                                                                                                     
   Single                                       59       4 (6.8)    1                          75    4 (5.3)    1                    
   Married or cohabited                         199      10 (5)     0.7 (0.2 to 2.4)    0.60   203   9 (4.4)    0.8 (0.2 to 2.8)     0.75
  Residence                                                                                                                          
   Rural                                        197      7 (3.6)    1                          172   5 (2.9)    1                    
   City                                         61       7 (11.5)   3.5 (1.2 to 10.5)   0.02   106   8 (7.5)    2.7 (0.9 to 8.6)     0.09
  Occupation                                                                                                                         
   Peasant                                      163      5 (3.1)    1                          138   0          1                    
   Employee                                     64       6 (9.4)    3.3 (1 to 11.1)     0.06   114   9 (7.9)    2 (1 to 12.6)        \<0.01
   Unemployed                                   31       3 (9.7)    3.4 (0.8 to 15)     0.11   26    4 (15.4)   3 (1 to 13.4)        \<0.01
  Age (years)                                                                                                                        
   \<35                                         73       5 (6.8)    1                          53    6 (11.3)   1                    
   35--45                                       108      6 (5.6)    0.8 (0.2 to 2.7)    0.72   119   6 (5)      0.4 (0.1 to 1.4)     0.15
   \>45                                         77       3 (3.9)    0.6 (0.1 to 2.4)    0.43   106   1 (0.9)    0.1 (0 to 0.6)       0.02
  Weight (kg)                                                                                                                        
   \<50                                         89       8 (9)      1                          49    4 (8.2)    1                    
   50--70                                       156      4 (2.6)    0.3 (0.1 to 0.9)    0.04   193   7 (3.6)    0.4 (0.1 to 1.5)     0.19
   \>70                                         13       2 (15.4)   1.8 (0.3 to 9.8)    0.47   36    2 (5.6)    0.7 (0.1 to 3.8)     0.64
  *HIV characteristics and treatment factors*                                                                                        
  Route of infection                                                                                                                 
   Heterosexual transmission                    159      8 (5)      1                          154   2 (0.6)    1                    
   Blood transmission                           86       4 (4.7)    0.9 (0.3 to 3.2)    0.9    61    3 (2)      3.9 (0.6 to 24.1)    0.14
   Intravenous drug use                         13       2 (15.4)   3.4 (0.6 to 18.2)   0.15   63    8 (10.5)   11.1 (2.3 to 53.7)   \<0.01
  Initial NRTI ART regimen                                                                                                           
   AZT-based regimen                            161      5 (3.1)    1                          188   10 (2.9)   1                    
   D4T-based regimen                            97       9 (9.3)    3.2 (1 to 9.8)      0.04   90    3 (1.6)    0.6 (0.2 to 2.3)     0.47
  Latest ART regimen                                                                                                                 
   AZT-based regimen                            181      8 (4.4)    1                          195   12 (3.2)   1                    
   D4T-based regimen                            77       6 (7.8)    1.8 (0.6 to 5.5)    0.28   83    1 (0.6)    0.2 (0 to 1.5)       0.11
  Switch ART regimen                                                                                                                 
   No                                           193      10 (5.2)   1                          174   6 (3.4)    1                    
   Yes                                          65       4 (6.2)    1.2 (0.4 to 4)      0.76   104   7 (6.7)    2 (0.7 to 6.2)       0.22
  Adverse effect                                                                                                                     
   No                                           195      9 (4.6)    1                          206   10 (4.9)   1                    
   Yes                                          63       5 (7.9)    1.8 (0.6 to 5.5)    0.32   72    3 (4.2)    0.9 (0.2 to 3.2)     0.81
  CD4 cell at baseline (2008)                                                                                                        
  \<350                                         244      14 (5.7)                              272   12 (2.3)   1                    
  ≥350                                          14       0          --                  0.36   6     1 (5)      4.3 (0.5 to 40)      0.2
  CD4 cell at 36 months (2011)                                                                                                       
  0--350                                        91       9 (9.9)    1                          138   11 (4.8)   1                    
  ≥350                                          167      5 (3)      0.3 (0.1 to 0.9)    0.03   140   2 (0.7)    0.2 (0 to 0.8)       0.02
  CD4 cell at 48 months (2012)                                                                                                       
  0--350                                        81       7 (8.6)    1                          122   11 (5.4)   1                    
  ≥350                                          177      7 (4)      0.4 (0.1 to 1.3)    0.13   156   2 (0.6)    0.1 (0 to 0.6)       0.01
  *Drug compliance factors*                                                                                                          
  Missed doses in past month                                                                                                         
   No                                           226      13 (5.8)   1                          246   6 (2.4)    1                    
   Yes                                          32       1 (3.1)    0.5 (0.1 to 4.2)    0.55   32    7 (21.9)   11.2 (3.5 to 35.9)   \<0.01

ART drug distribution location, willing to receive ART in the future, believe ART is health promoting, believe poor compliance contributes to HIVDR, degree of satisfaction on support of friends or relatives, frequency of taking drugs reminded by friends or relatives, and frequency of taking drugs reminded by doctors are not displayed as no statistical significant difference was found between categories.

ART, antiretroviral treatment; AZT, zidovudine; D4T, stavudine; HIVDR, HIV drug resistance; NRTI, nucleoside reverse-transcriptase inhibitors.

Of the 536 eligible participants, 51.8% were male, 76.5% were of Han nationality, 45.0% had an education level of elementary school or less, 56.2% were farmers and 10.6% were unemployed with the rest having regular income.

All regimens in this cohort remained 3TC based from 2008 to 2012. Initiated nucleoside reverse-transcriptase inhibitor (NRTI) regimens included zidovudine (AZT) (n=349, 65.1%) or stavudine (D4T) (n=187, 34.9%). Sixty-six (12.3%) participants later changed to tenofovir (TDF)-based regimen. Initiated non-nucleoside reverse-transcriptase inhibitor (NNRTI) regimens included nevirapine (n=421, 78.5%) or etravirine (n=115, 21.5%). Fifty-five (10.3%) participants later changed to LPV/r(Lopinavir/Ritonavir)-based regimen. One hundred and sixty-nine (31.5%) participants switched the initial ART regimen during 2008--2012, but no statistical significant difference was found in VF (p=0.74) and HIVDR (p=0.29) risk between participants who switched regimens and participants who did not switch regimens.

We found that 38.4% of participants were hesitant to accept ART in the future, 36.8% participants reported doubts whether ART was health promoting and 42.5% participants did not report that poor ART adherence necessarily contributed to HIVDR. Additionally, 40.5% of participants were not always satisfied with support from friends or relatives. Four hundred and seventy-two (88.1%) participants reported not missing a dose in the month prior to the date of the survey.

Multivariate model results ([table 3](#T3){ref-type="table"}) {#s4b}
-------------------------------------------------------------

###### 

Multivariate models of factors associated with virological failure (viral load ≥1000 copies/mL) and HIVDR (viral load ≥1000 copies/mL with drug resistance) stratified by sex

  Variables                                              Female (n=258)     Male (n=278)                                                                              
  ------------------------------------------------------ ------------------ -------------- ------------------- ------ ------------------- ------ -------------------- --------
  Ethnicity                                                                                                                                                           
   Han nationality                                                                         1                          1                          1                    
   Other minorities                                                                        4.8 (1.2 to 19.7)   0.03   2.9 (1.1 to 7.3)    0.02   12.2 (1.8 to 84.8)   0.01
  Residence                                                                                                                                                           
   Rural                                                                                   1                                                                          
   City                                                                                    2.4 (0.6 to 9.5)    0.22                                                   
  Age (years)                                                                                                                                                         
  \<35                                                                                                                                           1                    
  35--45                                                                                                                                         0.3 (0.1 to 1.4)     0.12
  \>45                                                                                                                                           0.03 (0 to 0.6)      0.02
  Weight (kg)                                                                                                                                                         
  \<50                                                                                     1                                                                          
  50--70                                                                                   0.3 (0.1 to 1.1)    0.08                                                   
  \>70                                                                                     4.2 (0.6 to 30)     0.15                                                   
  Route of infection                                                                                                                                                  
   Heterosexual transmission                             1                                                            1                          1                    
   Blood transmission                                    1.2 (0.5 to 3)     0.74                                      1.8 (0.6 to 5.8)    0.33   7 (0.8 to 64.4)      0.09
   Intravenous drug use                                  4.1 (1 to 17.7)    0.06                                      2.1 (0.8 to 5.4)    0.12   2.3 (0.3 to 16.1)    0.41
  Initial NRTI ART regimen                                                                                                                                            
   AZT-based regimen                                     1                                 1                                                                          
   D4T-based regimen                                     2.5 (1 to 6.1)     0.04           3.6 (1 to 12.6)     0.05                                                   
  ART drug distribution location                                                                                                                                      
   County hospital or CDC                                                                                             1                                               
   Township hospital/village clinic/medication monitor                                                                0.5 (0.2 to 1.3)    0.18                        
  Adverse effect                                                                                                                                                      
   No                                                    1                                                                                                            
   Yes                                                   2.3 (1 to 5.6)     0.06                                                                                      
  CD4 cell at baseline (2008)                                                                                                                                         
  \<350                                                                                                               1                                               
  ≥350                                                                                                                7.1 (1.1 to 45.8)   0.04                        
  CD4 cell at 36 months (2011)                                                                                                                                        
  \<350                                                  1                                 1                                                     1                    
  ≥350                                                   0.4 (0.2 to 1.1)   0.07           0.3 (0.1 to 0.9)    0.04                              0.3 (0 to 1.9)       0.2
  CD4 cell at 48 months (2012)                                                                                                                                        
  \<350                                                  1                                                                                       1                    
  ≥350                                                   0.6 (0.3 to 1.6)   0.36                                                                 0.1 (0 to 1)         0.05
  Missed doses in past month                                                                                                                                          
   No                                                                                                                 1                          1                    
   Yes                                                                                                                2.8 (1.1 to 7)      0.03   9.7 (2.1 to 44.1)    \<0.01
  Frequency of taking drugs reminded by doctors                                                                                                                       
   Often                                                                                                              1                                               
   Not often                                                                                                          0.4 (0.2 to 1.2)    0.12                        

ART, antiretroviral treatment; AZT, zidovudine; CDC, Centers for Disease Control and Prevention; D4T, stavudine; HIVDR, HIV drug resistance; NRTI, nucleoside reverse-transcriptase inhibitors.

As shown in [table 3](#T3){ref-type="table"}, minority male participants were at higher risk for both VF (aOR=2.9, 95% CI 1.1 to 7.3, p=0.02) and HIVDR (aOR=12.2, 95% CI 1.8 to 84.8, p=0.01) compared with Han nationality male participants, while female minorities were only at a higher risk for HIVDR (aOR=4.8, 95% CI 1.2 to 19.7, p=0.03).

Female participants initiating D4T-based regimens were at a higher risk for both VF (aOR=2.5, 95% CI 1 to 6.1, p=0.04) and HIVDR (aOR=3.6, 95% CI 1 to 12.6, p=0.05) versus those initiating an AZT-based regimen; interestingly, different from their female counterparts, male participants showed no such association (OR=0.6, 95% CI 0.3 to 1.4, p=0.24). Also, female participants had a higher risk of VF given adverse side effects (aOR=2.3, 95% CI 1 to 5.6, p=0.06). Male participants with missed doses in the month prior to the survey were at a higher risk of both VF (aOR=2.8, 95% CI 1.1 to 7, p=0.03) and HIVDR (aOR=9.7, 95% CI 2.1 to 44.1, p\<0.01) versus those without missed doses in the preceding month. Conversely, missed doses in prior month were not significantly associated with VF or HIVDR for women.

HIVDR and subtype ([table 4](#T4){ref-type="table"}) {#s4c}
----------------------------------------------------

###### 

HIVDR and subtype among 27 patients with HIVDR mutation detected at 2011 and/or 2012 stratified by sex

                         Female (%)   Male (%)   Mutations                 N (%)
  ---------------------- ------------ ---------- ------------------------- -----------
  Overall                14           13                                   
  Subtype                                                                  
   B                     5 (35.7)     3 (23.1)                             
   C                                  1 (7.7)                              
   CRF01_AE              2 (14.3)     1 (7.7)                              
   CRF07_BC              7 (50)       8 (61.5)                             
  Antiretroviral drug                                                      
   NNRTI (any)           14 (100)     13 (100)   NNRTI mutations (total)   27
   Efavirenz (EFV)       14 (100)     13 (100)   V90I                      1 (3.7)
  Nevirapine (NVP)       14 (100)     13 (100)   A98G                      2 (7.4)
  Etravirine (ETR)       6 (42.9)     8 (61.5)   K101E                     6 (22.2)
                                                 K103N                     11 (40.7)
                                                 V106A                     4 (14.8)
                                                 V108I                     6 (22.2)
                                                 E138A                     1 (3.7)
                                                 V179D/F                   3 (11.1)
                                                 Y181C                     5 (18.5)
                                                 G190A                     5 (18.5)
                                                 H221Y                     1 (3.7)
                                                 P225H                     3 (11.1)
                                                 F227L                     1 (3.7)
                                                 M230L                     1 (3.7)
   NRTI (any)            12 (85.7)    9 (69.2)   NRTI mutations (total)    21
   Lamivudine (3TC)      12 (85.7)    9 (69.2)   A62V                      1 (4.8)
  Azidothymidine (AZT)   2 (14.3)     2 (15.4)   D67G                      1 (4.8)
  Tenofovir (TDF)        1 (7.1)      3 (23.1)   T69N                      2 (9.5)
   Stavudine (D4T)       3 (21.4)     3 (23.1)   K70R/Q                    4 (19)
  Didanosine (DDI)       5 (35.7)     3 (23.1)   V75I/M                    2 (9.5)
  Abacavir (ABC)         12 (85.7)    9 (69.2)   M184V                     17 (81.0)
   Emtricitabine (FTC)   12 (85.7)    9 (69.2)   T215N                     1 (4.8)
                                                 K219E/Q                   2 (9.5)
   PI (any)              0            0          PI mutations (total)      0

HIVDR, HIV drug resistance; NNRTI, non-nucleoside reverse-transcriptase inhibitors; NRTI, nucleoside reverse-transcriptase inhibitors; PI, protease inhibitor.

HIVDR identified in our study was consistent with the NFATP-recommended ART regimen. All 27 participants detected with drug resistance had NNRTI mutations, 21 (77.8%) had NRTI mutations. The dominant subtype was CRF07_BC for both men (61.5%) and women (50%). All participants found with HIVDR had developed HIVDR towards NNRTI; 85.7% of male participants and 69.2% of female participants developed HIVDR towards NRTI; no protease inhibitor mutation was detected. There were no CRF08_BC subtypes detected in the study population.

Discussion {#s5}
==========

The 48-month risk of VF was 11.8% and HIVDR was 5.0%, which indicated relatively good treatment outcomes given meta-analysis suggested a 37 to 48-month HIVDR prevalence ranging from 3.04% to 47.92% in China,[@R9] similar to studies in China which estimated a 1-year HIVDR incidence of 3.5% in 2009 and 2.1% in 2012.[@R25] Our study substantiates the finding that VF and HIVDR largely decreased since the wide spread of 3TC-based regimens.[@R27] Studies have shown mixed findings of gender differences on ART adherence and treatment outcomes.[@R14] In our study, we found male participants had slightly higher risk of VF (12.2% vs 11.2%, p=0.72) but lower risk of HIVDR (4.7% vs 5.4%, p=0.69) than women. Drug adherence and adverse effects influenced our outcomes differently for men compared with women. Women's risks of VF and HIVDR were not associated with missing doses in the past month; also, few women missed doses relative to men, similar to two other studies in China suggesting women have better adherence behaviours.[@R30] Male participants were at higher risk of both VF and HIVDR if they reported missed doses. More detailed studies need to be conducted on the frequency and factors associated with missing treatment. However, female participants showed a higher risk of VF if they had adverse effect while men did not. This calls for further research of what types of adverse effects are occurring and how they affect ART adherence and virological outcomes across gender.

We found in this study that women, not men, who initiated D4T-based regimens were more susceptible to VF (women vs men: OR=2.3, 95% CI 1.0 to 5.7, p=0.06) and HIVDR (women vs men: OR=3.0, 95% CI 0.8 to 11.3, p=0.11), consistent with previous findings that D4T was more likely to increase the risk of mitochondrial toxicity in women.[@R32] Mitochondrial toxicity caused by D4T had been reported to cause many adverse effects such as lactic acidosis, lipodystrophy and peripheral neuropathy.[@R34] Following the WHO recommendation,[@R36] the NFATP advocated switching the first-line regimen from D4T to TDF in 2012. The percentage of people living with HIV initiating D4T-based regimen changed from 34.3% in 2010 to 10% in 2012 and 0.9% in 2014[@R37]; however, there were still 29.9% of participants in our study who were on D4T-based regimens in 2012. It was noteworthy that we did not see a statistical difference in VF (OR=1.4, 95% CI 0.4 to 4.2, p=0.60) and HIVDR (OR=1.0, 95% CI 0.2 to 4.2, p=0.98) between women who initiated and remained on D4T-based regimens and those who switched to AZT/TDF-based regimens. It is possible that women switched regimens because of VF; however, further studies need to be done to explore when to switch ART regimen for women receiving D4T-based regimens. It is important to mention that data on ART adherence and adverse effects were collected in 2012, when there were only four female participants still using D4T-based regimens who experienced VF. The sample size was not sufficient to explore whether D4T-based regimens affect drug adherence and adverse effects for women.

Though not associated with the VF and HIVDR outcomes, 38.4% of study participants reported that they would not 'always' be willing to take ART in the future, 36.8% reported not believing that ART is 'always' health promoting, and 42.5% reported not believing that poor compliance 'always' contributed to HIVDR. As willingness and these knowledge factors may impact more long-term VF and HIVDR outcomes, the motivations behind willingness and knowledge about VF and HIVDR warrant exploration.

Caution is needed when interpreting the study results from multivariate model that older age (\>45) was protective for HIVDR in men. There were only four male IDU participants with older age (\>45) in this study, the number is not sufficient to test for interaction. There is no association between HIVDR and age (OR=6.5, 95% CI 1.1 to 38.1, p=0.49) in the subanalysis we did among male IDU participants, after controlling for variables showed significance in the univariate model. A previous study in HIV-positive IDU population in China suggested that there is no association between VF and sex or age.[@R38] In this study, 61.5% of male participants with HIVDR became HIV infected via IDU, yet there were only 22.7% of male IDU participants.

In addition, we found that younger (\<45 years) IDU population was more likely to miss doses (18.6%) compared with heterosexual transmission population (8.8%) and blood transfusion transmission population (12.1%). This finding was consistent with studies that implied younger men were at a higher risk of drug abuse.[@R39] This result indicated that younger IDU population could be a main source of VF and HIVDR; therefore, they could be future targeted population for behavioural intervention.

The increased risk of VF and HIVDR in non-Han minorities, regardless of gender, may be due to logistical, cultural or social barriers faced by ethnic minorities which limit their adherence to ART. It has been reported that minorities tend to have lower social economic status than Han majorities, followed by lower education level and fewer access to health facilities.[@R41] It may be difficult for health professionals to reach for some minorities because of their more remote geographical locations. Additionally, several studies have reported that the percentage of high-risk populations such as female sex workers and IDUs was higher in minorities than of Han nationality.[@R42] The causes of this increased VF and HIVDR risk warrant further exploration, and ethnic minorities may be an important group to tailor adherence-focused interventions in China. The finding that higher CD4 cell count at follow-up was protective for VF and HIVDR was expected. NFATP changed treatment criteria from CD4 cell count ≤0.2x10\^9/L to CD4 cell count ≤0.3x10\^9/L following the WHO recommendation in 2011.[@R7] Our study indicated that male participants who initiated treatment in 2008 at CD4 cell count ≥0.35x10\^9/L were still at higher risk towards VF (aOR=7.1, 95% CI 1.1 to 45.8, p=0.04), supporting possible clinical benefits of initiating ART at higher CD4 cell counts \<0.5x10\^9/L as per WHO recommendation in 2013.[@R46]

Among participants infected by blood transmission, we only found HIVDR subtype B; only one subtype C was found in participants infected though IDU, the dominant subtype was CRF07_BC, found both in participants infected by heterosexual transmission and IDU. The most common NNRTI mutation sites were K103N (40.7%), K101E (22.2%) and V108I (22.2%); the most common NRTI mutation sites were M184V (81.0%) and K70R (19%). Interestingly, compared with a 1-year follow-up study in China with all participants initiated ART in 2011,[@R47] there is no V108I in their study and we did not find K65R in our study.

Study findings should be interpreted in light of several limitations. Though we did not account for transmitted drug resistance in this study, previous studies have found low transmitted drug resistance risk (\<5%) during this period[@R48];we could be fairly certain that participants were outcome free in 2008 as they were new ART initiators. Another limitation of our study is that the outcomes were measured in 2011 and 2012, and thus we may be missing transient VF outcomes. Also, route of transmission was collected in 2008 when assessing HIV infection among men who have sex with men was not part of data collection instruments; additionally, we do not have data on sex worker status. Roughly half of the study participants selected for possible inclusion in the study for having initiated first-line ART in 2008 were lost to follow-up by 2012, creating a possible selection bias for individuals with better ART adherence---this bias may underestimate the true VF and HIVDR risk and also limit the generalisability of our findings to better adherers. Additionally, given the demographic profile of the cohort, our findings are most generalisable to heterosexual Han nationals who are married/cohabiting and working as agricultural labourers in rural areas. Misclassification of self-reported data is possible, though we do not expect this misclassification to be differential by the outcome of interest and thus any such information bias would bias our results towards the null.

Conclusions {#s6}
===========

We found female participants initiating D4T versus AZT-based regimens were more vulnerable to VF and HIVDR, and we suggest future studies on whether and when to change ART regimen for women initiated with D4T-based regimen. Poor adherence was a risk factor among male participants who may benefit from reinforced adherence counselling or social support. Increased VF and HIVDR risk among non-Han minorities warrants further exploration, and ethnic minorities may be an important group to tailor adherence-focused interventions in China. Also, this study indicated that younger men who become infected through intravenous drug use may be groups to strategically focus counselling and increasing adherence support programme.

Supplementary Material
======================

###### Reviewer comments

###### Author\'s manuscript

**Contributors:** YR, WK, HX and YS designed the study. YR, HX, SL, LL, YM, HT, TZ, GS, CH, WK, XL and PL collected the data. CH, TT and LL conducted laboratory analysis. XL and WK analysed the data. KMW, VCM, YR, WK, HX, LL and YS interpreted the data. KMW, VCM, YR, WK, TT and YS drafted the report. All authors reviewed, revised and approved the final report.

**Funding:** This study was supported by Guangxi Center for Disease Control and Prevention, Nanning, China. The antiretroviral drugs used in this study were provided by NFATP.

**Competing interests:** None declared.

**Patient consent:** Obtained.

**Ethics approval:** National Center for AIDS/STD Control and Prevention of the Chinese Center for Disease Control and Prevention (NCAIDS, China CDC).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** No additional data are available.

[^1]: WK and TT contributed equally.
